Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-229-5872
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.70 million
Profitability
Miscellaneous
Employees124
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme Inc (NASDAQ:EPZM) posted its quarterly earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.02. The biopharmaceutical company earned $5.90 million during the quarter, compared to the consensus estimate of $0.32 million. Epizyme's revenue for the quarter was down 50.8% compared to the same quarter last year. During the same period last year, the business earned ($0.42) EPS. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
9 equities research analysts have issued 12 month target prices for Epizyme's stock. Their forecasts range from $11.00 to $25.00. On average, they anticipate Epizyme's stock price to reach $18.50 in the next year. This suggests a possible upside of 67.3% from the stock's current price. View Analyst Price Targets for Epizyme.
What is the consensus analysts' recommendation for Epizyme?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.
Has Epizyme been receiving favorable news coverage?
News coverage about EPZM stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Epizyme earned a news impact score of -1.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Epizyme.
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Allakos (ALLK), Nektar Therapeutics (NKTR), FibroGen (FGEN), Evotec (EVTCY), Alkermes (ALKS), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR) and HUTCHISON CHINA/S (HCM).
What other stocks do shareholders of Epizyme own?
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
- Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
- Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
- Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
- Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)
Who are Epizyme's major shareholders?
Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (11.27%), Vanguard Group Inc. (7.79%), BlackRock Inc. (7.07%), NEA Management Company LLC (4.82%), Rock Springs Capital Management LP (2.04%) and Victory Capital Management Inc. (1.85%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert B Bazemore. View Institutional Ownership Trends for Epizyme.
Which major investors are selling Epizyme stock?
EPZM stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Point72 Asset Management L.P., D. E. Shaw & Co. Inc., Artal Group S.A., A.R.T. Advisors LLC, Morgan Stanley, Virtus ETF Advisers LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros and Robert B Bazemore. View Insider Buying and Selling for Epizyme.
Which major investors are buying Epizyme stock?
EPZM stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Rhenman & Partners Asset Management AB, Renaissance Technologies LLC, Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, First Light Asset Management LLC and Alps Advisors Inc.. View Insider Buying and Selling for Epizyme.
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $11.06.
How big of a company is Epizyme?
Epizyme has a market capitalization of $1.01 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.
What is Epizyme's official website?
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
| Community Ranking: | | 2.8 out of 5 ( ) |
| Outperform Votes: | | 415 (Thanks for Voting!) |
| Underperform Votes: | | 314 (Thanks for Voting!) |
| Total Votes: | | 729 |
